.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Hormonal suppression effectively manages endometriosis symptoms and chronic pain. However, many clinicians express concern regarding endometriosis treatment bone health outcomes. Consequently, a recent systematic review published in Obstetrics & Gynecology evaluates how medical therapies influence bone mineral density (BMD).
Specifically, researchers analyzed 37 clinical studies after screening over 1,000 papers. Furthermore, the pooled results showed that GnRH agonists significantly reduced BMD after 12 months of use. In addition, both leuprolide and goserelin treatments led to a notable decrease in bone mass. Although add-back therapy helps, BMD nevertheless declined in most patients because of severe estrogen suppression. Similarly, dienogest also impacted bone health. For example, it was associated with lower BMD at both 6 and 12 months. Consequently, doctors should monitor these patients closely during treatment. Moreover, GnRH antagonists showed a significant decrease, particularly without add-back protocols. Therefore, clinicians must assess bone risks before starting long-term therapy.
Additionally, Indian guidelines from the Indian Fertility Society recommend limiting GnRH analogs since they cause significant bone loss. Furthermore, the ICMR "EndoCare India" model supports standardized care and regular screening. Thus, these proactive steps help ensure that bone preservation remains a clinical priority. Consequently, doctors must balance effective pain relief with the risk of future fractures. Moreover, regular BMD screening and nutritional support are essential for high-risk individuals. In summary, expert consensus is needed for better long-term bone management.
Based on the meta-analysis, GnRH antagonists without add-back therapy showed the largest BMD decrease at six months. Although GnRH agonists and dienogest also cause loss, the lack of add-back therapy significantly worsens the impact on bone mineral density.
Yes, add-back therapy is highly effective because it provides a low level of estrogen to protect the bones. However, it does not completely eliminate bone loss. Therefore, clinicians should still perform regular monitoring during extended treatment cycles.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A systematic review indicates that hormonal treatments for endometriosis, including GnRH agonists and dienogest, significantly decrease bone mineral density...
5 months ago
A large NHANES cohort study reveals that higher Healthy Eating Index scores significantly reduce all-cause mortality risk in CKD patients by 45%. This analysis highlights the importance of comprehensive diet quality and medical nutrition therapy in renal care to optimize long-term clinical survival.
Today
Explore real-world data showing how private oncogenetics and molecular tumor boards achieve 3-week consult turnaround, high ctDNA actionability, and vital germline variant detection, enhancing individualized cancer care and familial risk assessment.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Today
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
